跳至主要内容
临床试验/IRCT20090117001556N159
IRCT20090117001556N159尚未招募2 期

The effect of Rosiglitazone as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial

niversity of social welfare and rehabilitation sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Diagnosis of schizophrenia based on DSM-5
  • Age between 18-50
  • At least 2 years have been passed since the diagnosis
  • Have been stable with risperidone treatment for at least 2 months

排除标准

  • Head trauma
  • History of shock therapy during the last three months
  • Neurosurgery
  • Diagnosis of acute or chronic systemic disease
  • Alcohol or drug addiction in the last 6 months
  • Suicidal ideation
  • Pregnancy or lactation
  • IQ less than 70 based on the diagnosis of a psychiatrist
  • ECT during recent two months
  • Taking oral antipsychotics, excluding risperidone, in the past week or long-acting antipsychotics in the past month
  • The presence of another diagnosis in axis II
  • History of heart disease
  • Family history of heart disease and heart failure
  • Taking insulin
  • Liver disorders
  • The development of a drug complication that requires emergency action: edema, congestive heart failure, heart pain and changes in the basic ECG, hypoglycemia, the occurrence of malignant neuroleptic syndrome

研究者

发起方
niversity of social welfare and rehabilitation sciences

相似试验